Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673

INTRODUCTION: BMN 673 is a potent inhibitor of poly-ADP ribose polymerase (PARP) that is in clinical testing with a primary focus on BRCA-mutated cancers. BMN 673 is active both through inhibiting PARP catalytic activity and by tightly trapping PARP to DNA at sites of single strand breaks. METHODS:...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatr Blood Cancer
Hauptverfasser: Smith, Malcolm A., Hampton, Oliver A., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Carol, Hernan, Keir, Stephen T., Wu, Jianrong, Kurmasheva, Raushan T., Wheeler, David A., Houghton, Peter J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4456187/
https://ncbi.nlm.nih.gov/pubmed/25263539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25201
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge